A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

To join this study, you would need to have bowel cancer that has spread to other parts of your body. Your doctor would need to confirm that your cancer has the specific dMMR or MSI-H features. You can't have had previous chemotherapy or targeted treatments for your widespread cancer if you are joining a specific part of the study, but for an earlier part, previous treatments might be okay.

There are also some reasons why you might not be able to join. For example, if you have certain autoimmune conditions (where your body's immune system attacks itself), specific lung problems, or if you have HIV/AIDS. Your general health would also be assessed to make sure you are well enough to take part.

The detailed plan for taking part isn't fully explained here, but generally, participating in a study like this involves regular hospital visits for check-ups, blood tests, and scans to monitor your health and how the treatment is working. You would receive one of the study drugs or a combination of drugs. The total duration of the study, including how long you would receive treatment and how long you would be followed up afterwards, would be clearly explained by the study team. They would also detail how often you need to attend the clinic and what medical assessments you would undergo.